-
MDA 2026: Early trial of PGN-EDODM1 shows biomarker activity in DM1
PGN-EDODM1, Pepgen’s experimental therapy for myotonic dystrophy type 1 (DM1), was generally well tolerated in
-
Capricor Therapeutics Announces Positive Data from HOPE-3 Study of Deramiocel
Capricor Therapeutics has announced additional analyses and new functional outcomes data from the Phase 3








